Avanos Medical, Inc. (NYSE:AVNS) Short Interest Update

Avanos Medical, Inc. (NYSE:AVNS - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 888,700 shares, a growth of 25.7% from the February 13th total of 707,000 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily volume of 492,300 shares, the days-to-cover ratio is presently 1.8 days.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Avanos Medical from a "hold" rating to a "buy" rating in a report on Wednesday.

Insider Buying and Selling

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares of the company's stock, valued at approximately $1,251,216.75. This trade represents a 7.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.94% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AVNS. Janney Montgomery Scott LLC raised its position in Avanos Medical by 194.3% during the third quarter. Janney Montgomery Scott LLC now owns 35,918 shares of the company's stock worth $863,000 after acquiring an additional 23,714 shares during the period. KBC Group NV raised its position in shares of Avanos Medical by 63.0% during the 3rd quarter. KBC Group NV now owns 2,833 shares of the company's stock worth $68,000 after purchasing an additional 1,095 shares during the last quarter. Natixis Advisors LLC lifted its stake in Avanos Medical by 13.6% in the 3rd quarter. Natixis Advisors LLC now owns 21,452 shares of the company's stock valued at $515,000 after buying an additional 2,574 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Avanos Medical by 58.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,668 shares of the company's stock worth $1,097,000 after buying an additional 16,929 shares during the last quarter. Finally, King Luther Capital Management Corp purchased a new stake in Avanos Medical during the 3rd quarter worth approximately $544,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Stock Performance

NYSE AVNS traded down $0.10 during mid-day trading on Friday, reaching $14.67. 1,547,734 shares of the stock were exchanged, compared to its average volume of 293,146. The company has a market capitalization of $675.05 million, a P/E ratio of 43.16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The business's 50 day moving average is $15.84 and its 200-day moving average is $18.79. Avanos Medical has a 1 year low of $14.25 and a 1 year high of $25.36.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.40 by $0.03. The firm had revenue of $179.60 million for the quarter, compared to analysts' expectations of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. On average, equities research analysts forecast that Avanos Medical will post 1.32 EPS for the current fiscal year.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.